Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
10/5/26 Genmab (GMAB) Epkinly for Diffuse Large B-Cell Lymphoma (DLBCL) Subscribers Only Subscribers Only Subscribers Only
10/1/26 AgomAb Therapeutics (AGMB) AGMB-129 for Crohn's Disease Subscribers Only Subscribers Only Subscribers Only
10/1/26 Nektar Therapeutics (NKTR) Rezpeg for Atopic Dermatitis (Eczema) Subscribers Only Subscribers Only Subscribers Only
10/1/26 Eli Lilly (LLY) retatrutide for Obesity Subscribers Only Subscribers Only Subscribers Only
10/1/26 Eli Lilly (LLY) retatrutide for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
07/31/2025 Subscribers Only Subscribers Only Regulatory - sNDA/sBLA Filing
10/28/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/31/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
11/11/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
11/13/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update